Fulgent Common Stock vs Accounts Payable Analysis

FLGT Stock

USD 18.33 0.46 2.57%

Fulgent Genetics financial indicator trend analysis is much more than just examining Fulgent Genetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulgent Genetics is a good investment. Please check the relationship between Fulgent Genetics Common Stock and its Accounts Payable accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulgent Genetics Common Stock account and Accounts Payable. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Fulgent Genetics' Common Stock and Accounts Payable is -0.6. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Fulgent Genetics, assuming nothing else is changed. The correlation between historical values of Fulgent Genetics' Common Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Fulgent Genetics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock i.e., Fulgent Genetics' Common Stock and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.6

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Common Stock

Accounts Payable

An accounting item on the balance sheet that represents Fulgent Genetics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Fulgent Genetics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Fulgent Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Discontinued Operations is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 93.4 M in 2024, whereas Tax Provision is likely to drop slightly above 2.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	777.1M	366.9M	104.5M	180.0M
Total Revenue	992.6M	619.0M	289.2M	266.7M

Gross Profit Total Revenue

Fulgent Genetics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Common Stock Total Equity	Common Stock	Other Liab
Total Assets		0.92	0.86	1.0	0.99	0.97	-0.91	0.98	0.85	0.87	0.87	-0.18	0.43	0.9	0.64	0.93	0.67	0.84	0.92	0.88	0.97	0.9	0.96	-0.59	-0.59	0.8
Other Current Liab	0.92		0.94	0.9	0.92	0.88	-0.91	0.84	0.94	0.89	0.73	-0.15	0.4	0.84	0.87	0.88	0.88	0.66	0.92	0.95	0.84	0.88	0.85	-0.6	-0.6	0.63
Total Current Liabilities	0.86	0.94		0.84	0.83	0.76	-0.87	0.78	1.0	0.91	0.55	-0.31	0.48	0.92	0.9	0.88	0.9	0.61	0.93	0.99	0.72	0.95	0.72	-0.56	-0.56	0.47
Total Stockholder Equity	1.0	0.9	0.84		0.99	0.98	-0.9	0.99	0.84	0.86	0.88	-0.18	0.43	0.89	0.62	0.93	0.64	0.85	0.91	0.87	0.97	0.89	0.96	-0.59	-0.59	0.81
Net Tangible Assets	0.99	0.92	0.83	0.99		0.97	-0.93	0.97	0.82	0.88	0.88	-0.06	0.47	0.87	0.65	0.92	0.68	0.79	0.9	0.86	0.96	0.87	0.96	-0.6	-0.6	0.79
Property Plant And Equipment Net	0.97	0.88	0.76	0.98	0.97		-0.83	0.96	0.77	0.77	0.96	-0.16	0.27	0.78	0.54	0.87	0.57	0.87	0.86	0.81	1.0	0.78	1.0	-0.59	-0.59	0.9
Net Debt	-0.91	-0.91	-0.87	-0.9	-0.93	-0.83		-0.85	-0.85	-0.98	-0.66	-0.13	-0.72	-0.9	-0.81	-0.89	-0.83	-0.53	-0.9	-0.88	-0.79	-0.92	-0.79	0.58	0.58	-0.51
Retained Earnings	0.98	0.84	0.78	0.99	0.97	0.96	-0.85		0.77	0.82	0.88	-0.2	0.42	0.88	0.52	0.88	0.55	0.88	0.85	0.81	0.96	0.86	0.95	-0.48	-0.48	0.83
Accounts Payable	0.85	0.94	1.0	0.84	0.82	0.77	-0.85	0.77		0.89	0.56	-0.34	0.43	0.9	0.89	0.89	0.9	0.63	0.94	0.99	0.73	0.93	0.73	-0.6	-0.6	0.49
Cash	0.87	0.89	0.91	0.86	0.88	0.77	-0.98	0.82	0.89		0.57	0.05	0.74	0.94	0.83	0.91	0.85	0.51	0.93	0.92	0.74	0.96	0.72	-0.57	-0.57	0.43
Non Current Assets Total	0.87	0.73	0.55	0.88	0.88	0.96	-0.66	0.88	0.56	0.57		-0.14	0.06	0.58	0.31	0.73	0.34	0.87	0.69	0.62	0.97	0.57	0.97	-0.47	-0.47	0.98
Non Currrent Assets Other	-0.18	-0.15	-0.31	-0.18	-0.06	-0.16	-0.13	-0.2	-0.34	0.05	-0.14		0.46	-0.23	-0.03	-0.21	-0.01	-0.55	-0.22	-0.28	-0.2	-0.2	-0.2	0.14	0.14	-0.31
Other Assets	0.43	0.4	0.48	0.43	0.47	0.27	-0.72	0.42	0.43	0.74	0.06	0.46		0.66	0.53	0.49	0.54	-0.01	0.47	0.45	0.24	0.66	0.21	-0.24	-0.24	-0.11
Cash And Short Term Investments	0.9	0.84	0.92	0.89	0.87	0.78	-0.9	0.88	0.9	0.94	0.58	-0.23	0.66		0.72	0.92	0.74	0.68	0.92	0.91	0.77	0.99	0.74	-0.56	-0.56	0.5
Net Receivables	0.64	0.87	0.9	0.62	0.65	0.54	-0.81	0.52	0.89	0.83	0.31	-0.03	0.53	0.72		0.68	1.0	0.25	0.77	0.87	0.48	0.79	0.49	-0.49	-0.49	0.17
Common Stock Shares Outstanding	0.93	0.88	0.88	0.93	0.92	0.87	-0.89	0.88	0.89	0.91	0.73	-0.21	0.49	0.92	0.68		0.7	0.74	0.99	0.91	0.86	0.93	0.85	-0.78	-0.78	0.65
Inventory	0.67	0.88	0.9	0.64	0.68	0.57	-0.83	0.55	0.9	0.85	0.34	-0.01	0.54	0.74	1.0	0.7		0.27	0.79	0.89	0.5	0.8	0.52	-0.48	-0.48	0.2
Other Current Assets	0.84	0.66	0.61	0.85	0.79	0.87	-0.53	0.88	0.63	0.51	0.87	-0.55	-0.01	0.68	0.25	0.74	0.27		0.7	0.65	0.9	0.64	0.9	-0.45	-0.45	0.93
Other Stockholder Equity	0.92	0.92	0.93	0.91	0.9	0.86	-0.9	0.85	0.94	0.93	0.69	-0.22	0.47	0.92	0.77	0.99	0.79	0.7		0.96	0.83	0.93	0.83	-0.74	-0.74	0.61
Total Liab	0.88	0.95	0.99	0.87	0.86	0.81	-0.88	0.81	0.99	0.92	0.62	-0.28	0.45	0.91	0.87	0.91	0.89	0.65	0.96		0.77	0.94	0.77	-0.57	-0.57	0.54
Property Plant And Equipment Gross	0.97	0.84	0.72	0.97	0.96	1.0	-0.79	0.96	0.73	0.74	0.97	-0.2	0.24	0.77	0.48	0.86	0.5	0.9	0.83	0.77		0.76	1.0	-0.56	-0.56	0.93
Total Current Assets	0.9	0.88	0.95	0.89	0.87	0.78	-0.92	0.86	0.93	0.96	0.57	-0.2	0.66	0.99	0.79	0.93	0.8	0.64	0.93	0.94	0.76		0.74	-0.57	-0.57	0.48
Property Plant Equipment	0.96	0.85	0.72	0.96	0.96	1.0	-0.79	0.95	0.73	0.72	0.97	-0.2	0.21	0.74	0.49	0.85	0.52	0.9	0.83	0.77	1.0	0.74		-0.57	-0.57	0.93
Common Stock Total Equity	-0.59	-0.6	-0.56	-0.59	-0.6	-0.59	0.58	-0.48	-0.6	-0.57	-0.47	0.14	-0.24	-0.56	-0.49	-0.78	-0.48	-0.45	-0.74	-0.57	-0.56	-0.57	-0.57		1.0	-0.41
Common Stock	-0.59	-0.6	-0.56	-0.59	-0.6	-0.59	0.58	-0.48	-0.6	-0.57	-0.47	0.14	-0.24	-0.56	-0.49	-0.78	-0.48	-0.45	-0.74	-0.57	-0.56	-0.57	-0.57	1.0		-0.41
Other Liab	0.8	0.63	0.47	0.81	0.79	0.9	-0.51	0.83	0.49	0.43	0.98	-0.31	-0.11	0.5	0.17	0.65	0.2	0.93	0.61	0.54	0.93	0.48	0.93	-0.41	-0.41

Click cells to compare fundamentals

Fulgent Genetics Account Relationship Matchups

Fulgent Genetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	88.8M	700.5M	1.3B	1.4B	1.2B	1.3B
Other Current Liab	3.6M	35.0M	28.4M	24.2M	26.9M	28.3M
Total Current Liabilities	6.0M	131.1M	112.8M	116.2M	73.0M	49.4M
Total Stockholder Equity	82.8M	569.4M	1.2B	1.3B	1.1B	1.2B
Net Tangible Assets	82.8M	569.4M	1.2B	973.0M	1.1B	1.2B
Property Plant And Equipment Net	6.0M	40.2M	62.3M	81.4M	95.6M	100.4M
Net Debt	(9.3M)	(71.6M)	(143.6M)	(58.9M)	(82.2M)	(78.1M)
Retained Earnings	(63.4M)	150.9M	657.6M	801M	633.2M	664.8M
Accounts Payable	1.6M	26.5M	20.5M	23.1M	15.4M	10.3M
Cash	12.0M	87.4M	164.9M	79.5M	97.5M	50.9M
Non Current Assets Total	12.0M	84.7M	204.3M	480.4M	727.5M	763.9M
Non Currrent Assets Other	(36.8M)	(88.0M)	142.0M	(287.4M)	22.7M	23.9M
Other Assets	251K	44.5M	912.6M	26.6M	1.0	0.95
Cash And Short Term Investments	70.2M	431.9M	935.5M	852.9M	424.2M	312.5M
Net Receivables	6.6M	204.1M	143.3M	52.7M	57.4M	52.9M
Common Stock Shares Outstanding	18.7M	24.1M	31.0M	31.0M	29.8M	23.5M
Liabilities And Stockholders Equity	88.8M	700.5M	1.3B	1.4B	1.2B	1.3B
Inventory	277K	16.5M	12.2M	4.3M	5.8M	4.4M
Other Current Assets	277K	3.7M	6.0M	44.5M	26.2M	27.6M
Other Stockholder Equity	146.1M	418.1M	501.9M	486.6M	501.7M	263.1M
Total Liab	6.0M	131.1M	112.8M	116.2M	102.0M	52.6M
Property Plant And Equipment Gross	8.6M	41.0M	81.9M	124.6M	135.1M	141.9M
Total Current Assets	76.8M	615.7M	1.1B	905.6M	507.8M	365.6M
Accumulated Other Comprehensive Income	146K	438K	(759K)	(20.9M)	1.2M	1.3M
Property Plant Equipment	8.6M	40.2M	62.3M	98.9M	113.8M	119.4M
Retained Earnings Total Equity	(63.0M)	(63.4M)	150.9M	657.6M	756.2M	794.0M
Short Term Investments	58.3M	344.4M	770.7M	773.4M	326.7M	326.9M
Non Current Liabilities Total	2.3M	959K	7.5M	28.1M	29.0M	30.5M
Capital Surpluse	114.2M	146.1M	418.1M	501.9M	577.2M	606.1M
Long Term Investments	42.8M	132.5M	507.0M	339.0M	444.0M	466.2M
Non Current Liabilities Other	2.3M	959K	7.5M	28.1M	11.0M	6.8M
Net Invested Capital	82.8M	584.4M	1.2B	1.3B	1.1B	688.3M
Net Working Capital	33.4M	393.5M	961.6M	539.8M	434.8M	381.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC